Mechanisms of acquired resistance to 2-(4-aminophenyl)benzothiazole (CJM 126, NSC 34445)
2000
Understanding Resistance to Cancer Drug CJM 126
publication
Author Information
Author(s): Bradshaw T D, Chua M-S, Orr S, Matthews C S, Stevens M F G
Primary Institution: Cancer Research Laboratories, School of Pharmaceutical Sciences, University of Nottingham
Hypothesis
What mechanisms lead to acquired resistance to the cancer drug CJM 126 in breast cancer cells?
Conclusion
The study found that certain breast cancer cell lines developed resistance to CJM 126, potentially due to increased expression of specific proteins.
Supporting Evidence
- CJM 126 effectively inhibits growth in certain breast cancer cell lines.
- Cell lines developed resistance to CJM 126 after long-term exposure.
- Increased expression of bcl-2 and p53 proteins may contribute to resistance.
- Resistance cells showed different drug localization and metabolism compared to sensitive cells.
Takeaway
Some breast cancer cells can become resistant to a drug called CJM 126, making it less effective, and this might be because of changes in the cells' proteins.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website